가족성 아밀로이드 다발신경병증 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global familial amyloid polyneuropathy therapeutics market size is expected to reach USD 7.16 Billion in 2034 from USD 3.39 Billion in 2025, growing at a CAGR of 8.67 during 2026-2034.This market is expanding due to the increasing focus on rare diseases and the development of targeted therapies. Familial amyloid polyneuropathy is a genetic disorder that affects the nervous system, leading to progressive disability. The growing awareness of rare diseases and advancements in genetic research are key factors driving market growth. Pharmaceutical companies are investing heavily in research and development to create effective treatments for this condition, which is contributing to market expansion.

Key drivers include the development of innovative therapies such as gene-silencing drugs and liver transplantation techniques. The increasing availability of advanced diagnostic tools is enabling early detection and treatment, improving patient outcomes. Regulatory support and incentives for orphan drugs are also encouraging the development of new therapies. Additionally, collaborations between research institutions and pharmaceutical companies are accelerating the introduction of novel treatments.

Looking ahead, the familial amyloid polyneuropathy therapeutics market is expected to witness significant advancements in treatment options. Companies are likely to focus on personalized medicine and targeted therapies to improve efficacy and reduce side effects. The integration of advanced technologies such as gene editing and RNA-based treatments will further enhance therapeutic outcomes. As research continues to progress, the market is anticipated to grow steadily and offer improved solutions for patients.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug Type

• Inotersen
• Tafamidis
• Patisiran
• Others

By Disease Type

• Familial Amyloid Polyneuropathy-I (FAP-I)
• Familial Amyloid Polyneuropathy-II (FAP-II)
• Familial Amyloid Polyneuropathy-III (FAP-III)
• Familial Amyloid Polyneuropathy-IV (FAP-IV)

By Gender Type

• Male
• Female

By Distribution Channel

• Hospital Pharmacies
• Retail pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc., Proclara Biosciences, Arcturus Therapeutics Inc., Eidos Therapeutics, Inc., Prothena Corporation plc, BridgeBio Pharma, Inc., SOM Biotech, Intellia Therapeutics, Inc., Akcea Therapeutics, Inc., Neurimmune Holding AG, Arcturus Therapeutics, Inc., Proclara Biosciences, Inc., Regeneron Pharmaceuticals, Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Inotersen Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Tafamidis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Patisiran Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Type
• 5.2. Familial Amyloid Polyneuropathy-I (FAP-I) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Familial Amyloid Polyneuropathy-II (FAP-II) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Familial Amyloid Polyneuropathy-III (FAP-III) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Familial Amyloid Polyneuropathy-IV (FAP-IV) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS MARKET: BY GENDER TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Gender Type
• 6.2. Male Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Female Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Type
  • 8.2.2 By Disease Type
  • 8.2.3 By Gender Type
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Type
  • 8.3.2 By Disease Type
  • 8.3.3 By Gender Type
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Type
  • 8.4.2 By Disease Type
  • 8.4.3 By Gender Type
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Type
  • 8.5.2 By Disease Type
  • 8.5.3 By Gender Type
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Type
  • 8.6.2 By Disease Type
  • 8.6.3 By Gender Type
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Pfizer Inc
  • 10.2.2 Alnylam Pharmaceuticals Inc
  • 10.2.3 Ionis Pharmaceuticals Inc
  • 10.2.4 Corino Therapeutics Inc
  • 10.2.5 Proclara Biosciences
  • 10.2.6 Arcturus Therapeutics Inc
  • 10.2.7 Eidos TherapeuticsInc
  • 10.2.8 Prothena Corporation Plc
  • 10.2.9 BridgeBio PharmaInc
  • 10.2.10 SOM Biotech
  • 10.2.11 Intellia TherapeuticsInc
  • 10.2.12 Akcea TherapeuticsInc
  • 10.2.13 Neurimmune Holding AG
  • 10.2.14 Arcturus TherapeuticsInc
  • 10.2.15 Proclara BiosciencesInc
  • 10.2.16 Regeneron PharmaceuticalsInc